 |
2 Products |  |
0 Diseases | | 2 Products |
|
1 Trial |  |
38 News |  |
- |||||| daleuton oral (DS107 oral) / DS Biopharma
Trial termination: Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Nov 28, 2022
P2, N=219, Terminated, Sponsor: DS Biopharma
Completed --> Terminated; Based on Interim Analysis results
- |||| daleuton oral (DS107 oral) / DS Biopharma
Trial completion: Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Feb 16, 2021
P2, N=219, Completed, Sponsor: DS Biopharma
Completed --> Terminated; Based on Interim Analysis results Recruiting --> Completed
- dihomo gamma linolenic acid (DS107 oral) / DS Biopharma, DSP107 / Kahr Medical, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses (Channel 7 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1505;
Moreover, binding of DSP107 to CD47 enables the 4-1BBL-mediated costimulation of antitumor T cell cytotoxicity. Thus, DSP107 activates both innate and adaptive anticancer immunity and may be of use for the treatment of DLBCL alone or in combination with RTX.
- || daleuton oral (DS107 oral) / DS Biopharma
Trial completion date, Trial primary completion date: Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Jul 23, 2020
P2, N=200, Recruiting, Sponsor: DS Biopharma
Thus, DSP107 activates both innate and adaptive anticancer immunity and may be of use for the treatment of DLBCL alone or in combination with RTX. Trial completion date: Aug 2020 --> Dec 2020 | Trial primary completion date: Jul 2020 --> Nov 2020
- | dihomo gamma linolenic acid (DS107 oral) / DS Biopharma
Preclinical, Journal: A novel orally available delta-5 desaturase inhibitor prevents atherosclerotic lesions accompanied with changes of fatty acid composition and eicosanoid production in ApoE knockout mice. (Pubmed Central) - Apr 26, 2020
Delta-5 desaturase (D5D), encoded by fatty acid desaturase 1 (Fads1), is the rate-limiting enzyme for the conversion from dihomo-γ-linolenic acid (DGLA) to arachidonic acid (AA) in the ω-6 polyunsaturated fatty acid pathway...We conclude that compound-326 prevented the progression of atherosclerosis in Western-diet fed ApoE KO mice via anti-inflammatory effects, suggesting that D5D inhibitors can be a novel remedy for preventing CV events. SIGNIFICANCE STATEMENT: This study shows a D5D specific and orally available potent inhibitor provided the first evidence to support the concept that D5D inhibitors will be a novel remedy for preventing atherosclerosis and subsequent CV events through a novel anti-inflammatory mechanism.
- | dihomo gamma linolenic acid (DS107 oral) / DS Biopharma
Preclinical, Journal: Oral administration of whole dihomo-γ-linolenic acid-producing yeast suppresses allergic contact dermatitis in mice. (Pubmed Central) - Jan 15, 2020
Taking advantage of well-known safety of S. cerevisiae, we previously investigated the efficacy of heat-killed whole DGLA-producing yeast cells on irritant contact dermatitis, and showed that oral intake of this yeast significantly suppressed inflammatory reactions, whereas no such suppression was observed by the intake of 25 times the amount of purified DGLA. Since this method is considered to be a simple and efficient way to suppress inflammation, we examined its effectiveness against allergic contact dermatitis (ACD) in this study and showed that this method was also effective against ACD.
- ||| daleuton oral (DS107 oral) / DS Biopharma
Enrollment open: Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Dec 5, 2019
P2, N=200, Recruiting, Sponsor: DS Biopharma
Since this method is considered to be a simple and efficient way to suppress inflammation, we examined its effectiveness against allergic contact dermatitis (ACD) in this study and showed that this method was also effective against ACD. Not yet recruiting --> Recruiting
- | daleuton oral (DS107 oral) / DS Biopharma
Trial initiation date: Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Jul 24, 2019
P2, N=200, Not yet recruiting, Sponsor: DS Biopharma
Not yet recruiting --> Recruiting Initiation date: Jun 2019 --> Sep 2019
- | dihomo gamma linolenic acid (DS107 oral) / DS Biopharma, S-equol (AUS131) / Ausio Pharmaceuticals, University of Kansas Medical Center
Clinical, Journal: A liposome-based formulation containing equol, dihomo-γ-linolenic acid (DGLA), and propionyl-L-carnitine to prevent and treat hair loss: a prospective investigation. (Pubmed Central) - Jun 19, 2019
Furthermore, significant increase in anagen hair and a significant decrease in telogen hair were observed starting from 3 months in male and 1 month in female patients. Thus, the formulations under investigation were effective in attenuating androgenic alopecia-related hair loss in men and women .
- |||| daleuton oral (DS107 oral) / DS Biopharma
New P2 trial: Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Jan 24, 2019
P2, N=200, Not yet recruiting, Sponsor: DS Biopharma
- |||| daleuton oral (DS107 oral) / DS Biopharma
Trial completion: Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients (clinicaltrials.gov) - Sep 18, 2018
P2b, N=321, Completed, Sponsor: DS Biopharma
Thus, the formulations under investigation were effective in attenuating androgenic alopecia-related hair loss in men and women . Active, not recruiting --> Completed
- |||| Galepa (daleuton topical) / DS Biopharma
Trial completion: Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD) (clinicaltrials.gov) - Sep 18, 2018
P2b, N=327, Completed, Sponsor: DS Biopharma
Active, not recruiting --> Completed Recruiting --> Completed
- || Galepa (daleuton topical) / DS Biopharma
Trial primary completion date: Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD) (clinicaltrials.gov) - Jun 28, 2018
P2b, N=300, Recruiting, Sponsor: DS Biopharma
Recruiting --> Completed Trial primary completion date: Mar 2018 --> Jul 2018
- ||| daleuton oral (DS107 oral) / DS Biopharma
Enrollment closed: Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients (clinicaltrials.gov) - Jun 28, 2018
P2b, N=300, Active, not recruiting, Sponsor: DS Biopharma
Trial primary completion date: Mar 2018 --> Jul 2018 Recruiting --> Active, not recruiting
- |||| daleuton oral (DS107 oral) / DS Biopharma
Enrollment open: Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients (clinicaltrials.gov) - Mar 9, 2018
P2b, N=300, Recruiting, Sponsor: DS Biopharma
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- ||| daleuton oral (DS107 oral) / DS Biopharma
Enrollment closed, Trial primary completion date: Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients (clinicaltrials.gov) - Mar 6, 2018
P2b, N=300, Active, not recruiting, Sponsor: DS Biopharma
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2018 --> May 2018
- || Galepa (daleuton topical) / DS Biopharma
Trial primary completion date: Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD) (clinicaltrials.gov) - Jan 5, 2018
P2b, N=300, Recruiting, Sponsor: DS Biopharma
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2018 --> May 2018 Trial primary completion date: Jun 2017 --> Mar 2018
- || daleuton oral (DS107 oral) / DS Biopharma
Trial primary completion date: Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients (clinicaltrials.gov) - Jan 5, 2018
P2b, N=300, Recruiting, Sponsor: DS Biopharma
Trial primary completion date: Jun 2017 --> Mar 2018 Trial primary completion date: Jun 2017 --> Feb 2018
- |||| Galepa (daleuton topical) / DS Biopharma
Enrollment open: Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD) (clinicaltrials.gov) - Feb 3, 2017
P2b, N=300, Recruiting, Sponsor: DS Biopharma
Trial primary completion date: Jun 2017 --> Feb 2018 Not yet recruiting --> Recruiting
- |||| daleuton oral (DS107 oral) / DS Biopharma
Enrollment open: Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients (clinicaltrials.gov) - Feb 3, 2017
P2b, N=300, Recruiting, Sponsor: DS Biopharma
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| daleuton oral (DS107 oral) / DS Biopharma
Enrollment change: Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients (clinicaltrials.gov) - Oct 18, 2016
P2b, N=300, Not yet recruiting, Sponsor: DS Biopharma
Not yet recruiting --> Recruiting N=240 --> 300
- |||||| Galepa (daleuton topical) / DS Biopharma
New P2b trial: Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD) (clinicaltrials.gov) - Oct 6, 2016
P2b, N=300, Not yet recruiting, Sponsor: DS Biopharma
- |||||| daleuton oral (DS107 oral) / DS Biopharma
New P2b trial: Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients (clinicaltrials.gov) - Aug 12, 2016
P2b, N=240, Not yet recruiting, Sponsor: DS Biopharma
- |||| daleuton oral (DS107 oral) / DS Biopharma
Trial completion: Oral DS107 in Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Jan 26, 2016
P2, N=102, Completed, Sponsor: Dignity Sciences Ltd.
N=240 --> 300 Active, not recruiting --> Completed
- ||| daleuton oral (DS107 oral) / DS Biopharma
Enrollment closed, Trial primary completion date: Oral DS107 in Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Oct 7, 2015
P2, N=100, Active, not recruiting, Sponsor: Dignity Sciences Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Nov 2015
- daleuton oral (DS107 oral) / DS Biopharma
Enrollment open, Enrollment change, Trial initiation date, Trial primary completion date: Oral DS107 in Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Feb 5, 2015
P2, N=100, Recruiting, Sponsor: Dignity Sciences Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Nov 2015 Suspended --> Recruiting | N=150 --> 100 | Initiation date: Sep 2014 --> Jan 2015 | Trial primary completion date: Mar 2015 --> Aug 2015
- daleuton oral (DS107 oral) / DS Biopharma
Trial suspension: Oral DS107 in Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Sep 10, 2014
P2, N=150, Suspended, Sponsor: Dignity Sciences Ltd.
Suspended --> Recruiting | N=150 --> 100 | Initiation date: Sep 2014 --> Jan 2015 | Trial primary completion date: Mar 2015 --> Aug 2015 Not yet recruiting --> Suspended
- | daleuton oral (DS107 oral) / DS Biopharma
New P2 trial: Oral DS107 in Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Aug 7, 2014
P2, N=150, Not yet recruiting, Sponsor: Dignity Sciences Ltd.
- | Galepa (daleuton topical) / DS Biopharma
New P2 trial: Safety and Efficacy Study of DGLA Cream in Patients with Acne Vulgaris (EUDRACT) - Dec 26, 2012
P2, N=150, Ongoing, Sponsor: Dignity Sciences Limited
- Galepa (daleuton topical) / DS Biopharma
Enrollment change: Safety and Efficacy Study of DGLA Cream in Patients with Atopic Dermatitis (EUDRACT) - Dec 4, 2012
P2, N=200, Ongoing, Sponsor: Dignity Sciences Limited
Not yet recruiting --> Suspended N=100 --> 200
- | Galepa (daleuton topical) / DS Biopharma
New P2 trial: Safety and Efficacy Study of DGLA Cream in Patients with Atopic Dermatitis (EUDRACT) - Oct 8, 2012
P2, N=200, Ongoing, Sponsor: Dignity Sciences Limited